Related Experiment Video
Updated: May 6, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.5K
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Pamela S Gaskin1, Peter S Chami2,3
1Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados.
Summary
Individual responses to GLP-1 and GIP analogs for type 2 diabetes and obesity vary. Higher baseline weight, BMI, HbA1c, insulin resistance, and certain demographics predict poor weight loss response to these crucial medications.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) analogs represent advancements in treating type 2 diabetes and obesity.
- Significant inter-individual variability exists in patient responses to these pharmacotherapies.
Purpose of the Study:
- To systematically review factors associated with minimal or no weight loss response to GLP-1 and GIP analog therapies.
- To identify predictors of suboptimal efficacy for personalized obesity pharmacotherapy.
Main Methods:
- Systematic literature review.
- Analysis of factors including baseline metabolic parameters, genetic predispositions, adherence, lifestyle, and demographics.
Main Results:
- Predictors of poor weight loss response include higher baseline body weight, BMI, HbA1c, and insulin resistance.
- Genetic variants (e.g., GLP1R), male sex, older age, and lower treatment adherence are associated with reduced efficacy.
- Metabolic health, lifestyle, and potentially gut microbiome composition influence weight loss outcomes.
Conclusions:
- Understanding predictors of low response is crucial for optimizing GLP-1/GIP analog treatment strategies.
- Personalized medicine approaches are needed to tailor obesity pharmacotherapy for improved patient outcomes.
- Further research in diverse populations is required to develop clinical decision-making tools.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958